EPI Shares Epiminder Limited
ASX · ASXLast in our picks 2026-10-05 — not in the current list; analysis below is from that screen
Emerging neurodiagnostics play with catalyst-rich development pathway.
Signal breakdown
- ▸Upcoming 2026 inflection points could re-rate shares.
- ▾Below 50-day MA (-17.25%)
- ▾Near 52-week low (1.2% of range)
Is EPI a buy right now?
Trend: EPI is trading below the 50-day average (-11.67%), RSI 55 — neutral momentum, with a 3-month return of -7.02%.
Valuation & quality: Epiminder Limited trades on forward P/E -2.4, price-to-book 0.70; fundamentals show net margin 0.0%, return on equity -301.9%, revenue growth 677.6% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$2.22 (+737.9% vs the last close; range A$2.21 – A$2.23), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Emerging neurodiagnostics play with catalyst-rich development pathway.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -27.10% | -9.70% | -28.60% | -20.00% | -12.50% | +21.40% | -23.50% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Epiminder Limited
Epiminder Limited engages in the development and manufacture of monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. The company offers Minder system, an electroencephalographic (EEG) recording and transmitting device implanted under the scalp.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.